135 related articles for article (PubMed ID: 12505053)
1. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin.
Riggs DR; Jackson B; Vona-Davis L; McFadden D
J Surg Res; 2002 Dec; 108(2):279-84. PubMed ID: 12505053
[TBL] [Abstract][Full Text] [Related]
2. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma.
McFadden DW; Riggs DR; Jackson BJ; Vona-Davis L
Am J Surg; 2003 Nov; 186(5):552-5. PubMed ID: 14599624
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis.
Riggs DR; Jackson BJ; Vona-Davis L; Nigam A; McFadden DW
Am J Surg; 2005 Jun; 189(6):680-4. PubMed ID: 15910720
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
Lamm DL; DeHaven JI; Riggs DR; Ebert RF
J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
[TBL] [Abstract][Full Text] [Related]
5. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results.
Linn JF; Black P; Derksen K; Rübben H; Thüroff JW
Eur Urol; 2000; 37 Suppl 3():34-40. PubMed ID: 10828685
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model.
Swerdlow RD; Ratliff TL; La Regina M; Ritchey JK; Ebert RF
J Urol; 1994 Jun; 151(6):1718-22. PubMed ID: 8189604
[TBL] [Abstract][Full Text] [Related]
7. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.
Lamm DL; Dehaven JI; Riggs DR
Eur Urol; 2000; 37 Suppl 3():41-4. PubMed ID: 10828686
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic Potential of Mollusk Hemocyanins in Combination with Human Vaccine Adjuvants in Murine Models of Oral Cancer.
Mora Román JJ; Del Campo M; Villar J; Paolini F; Curzio G; Venuti A; Jara L; Ferreira J; Murgas P; Lladser A; Manubens A; Becker MI
J Immunol Res; 2019; 2019():7076942. PubMed ID: 30847353
[TBL] [Abstract][Full Text] [Related]
9. [Hemocyanins as immunostimulants].
Del Campo M; Arancibia S; Nova E; Salazar F; González A; Moltedo B; De Ioannes P; Ferreira J; Manubens A; Becker MI
Rev Med Chil; 2011 Feb; 139(2):236-46. PubMed ID: 21773663
[TBL] [Abstract][Full Text] [Related]
10. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
[TBL] [Abstract][Full Text] [Related]
11. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
Jurincic-Winkler CD; Metz KA; Beuth J; Klippel KF
Eur Urol; 2000; 37 Suppl 3():45-9. PubMed ID: 10828687
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin.
Vona-Davis L; Vincent T; Zulfiqar S; Jackson B; Riggs D; McFadden DW
J Gastrointest Surg; 2004 Dec; 8(8):1018-23. PubMed ID: 15585389
[TBL] [Abstract][Full Text] [Related]
13. Postoperative long-term course of peripheral blood immune parameters and immunomodulating effects of keyhole limpet hemocyanin in patients with nonmetastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Eur Urol; 1992; 21(4):315-22. PubMed ID: 1459154
[TBL] [Abstract][Full Text] [Related]
14. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
15. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1992; 48(1):1-8. PubMed ID: 1598724
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
17. Marine tumor vaccine carriers: structure of the molluscan hemocyanins KLH and htH.
Markl J; Lieb B; Gebauer W; Altenhein B; Meissner U; Harris JR
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R3-9. PubMed ID: 11768622
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of leptin on cancer in vitro.
Somasundar P; Yu AK; Vona-Davis L; McFadden DW
J Surg Res; 2003 Jul; 113(1):50-5. PubMed ID: 12943810
[TBL] [Abstract][Full Text] [Related]
19. Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo.
Rizvi I; Riggs DR; Jackson BJ; McFadden DW
Am J Surg; 2007 Nov; 194(5):628-32. PubMed ID: 17936425
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
